ERBB2 and breast cancer: Further analysis of 129 breast cancer patients showed that high expression of GALNT14 in breast cancer tissues was associated with higher HER2 (76.7% vs. 58.1%, p = 0.038), higher clinical stages (p < 0.0001), and shorter DFS (p = 0.029).